Creat Explores Options for German Blood Plasma Firm Biotest
(Bloomberg) -- China's Creat Group Corp. is weighing options for its stake in German blood-plasma supplier Biotest AG, an attempt to unwind a years-long investment that was upended by U.S. intervention.
Biotest has been informed by its major shareholder Tiancheng International Investment Ltd., a unit of Creat, that it's in the early stage of considering strategic options for its holding, the German company said in a statement Tuesday. The deliberations may not result in a transaction, according to the statement, which confirmed an earlier Bloomberg News report.
Creat is working with Bank of America Corp. on a potential sale of its stake in Biotest, people familiar with the matter said earlier. The Chinese company has started gauging interest in Biotest from potential buyers, the people said, asking not to be identified because the information is private.
Biotest's common shares were up 17% at 1:05 p.m. Tuesday in Frankfurt, putting the company on track for its biggest daily gain since January 2018 and giving it a market value of about 1.3 billion euros ($1.6 billion).
Any divestment would see the acquisitive Chinese group unwind part of a series of overseas acquisitions that began in 2016. Creat also owns the U.K.'s Bio Products Laboratory Ltd. and a stake in domestic blood plasma firm Shanghai RAAS Blood Products Co. Its shopping spree drew scrutiny from the Committee on Foreign Investment in the U.S., which first forced it to sell Biotest's U.S. operations.
Earlier this year, Creat also offloaded BPL's U.S. plasma centers. The sale of the U.S. activities hurts the overall scale of Creat's blood plasma business and undermines the strategic rationale for the acquisitions, the people said. North America historically accounts for about half the global blood plasma market, according to Biotest data.
Any sale process would likely attract buyout firms. Private equity firm Triton has its “broader radar” of potential targets, managing partner Martin Huth told journalists earlier this year.
Creat currently owns about 90% of Biotest's common stock, while the German firm's preference shares are held by other investors, according to data compiled by Bloomberg.
Biotest, which has more than 1,900 employees, provides plasma to treat patients with blood coagulation disorders, auto-immune diseases and immune deficiencies, according to its website. The company also develops monoclonal antibodies to treat blood cancers and lupus.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.